Finding the right dose of enzalutamide for older men with prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether older men (75+) with advanced prostate cancer need a different dose of enzalutamide than younger patients. Enzalutamide is a hormone therapy that slows prostate cancer growth. The trial will help doctors give the safest, most effective dose for elderly patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 75 or older
- You have advanced prostate cancer that enzalutamide is approved to treat (biochemical recurrence, metastatic castration-sensitive, or non-metastatic castration-resistant types)
- You are receiving or will receive hormone-blocking therapy (LHRH medication or surgery) along with enzalutamide
- You can attend study visits and provide blood samples on the schedule required
- You don't have bone pain requiring opioids, spinal cord compression risk, or risk of bone fractures from metastases
- You don't take medications that strongly interact with enzalutamide, and you don't have seizure history, dementia, or severe kidney/liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a lower dose of the medication enzalutamide works and how tolerable it is for men with advanced prostate cancer. The goal is to see if a lower dose can still help while reducing side effects.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Hear when a new Prostate Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.